Summary
Global Markets Direct's, 'Spinal Cord Injury - Pipeline Review, H1 2016', provides an overview of the
Spinal Cord Injury pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Spinal Cord
Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type.
Browse Detail Report With TOC @
http://hexareports.com/report/spinal-cord-injury-pipeline-review-h1-2016/details
The report also covers the descriptive pharmacological action of the therapeutics, its complete research
and development history and latest news and press releases. Additionally, the report provides an
overview of key players involved in therapeutic development for Spinal Cord Injury and features
dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Direct's proprietary databases, company/university websites, clinical trial registries,
Hexa Reports
Market Research Reports and Insightful Company Profiles
conferences, SEC filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to
ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios,
enhances decision making...